A clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta, led by Dr. Tobey MacDonald, showed positive results for Moleculin Biotech’s WP1066, published in the Journal of Clinical Investigation Insight. The trial demonstrated WP1066’s ability to induce anti-tumor immune responses, leading to plans for a Phase 2 trial. The study included children with high-grade glioma, with promising results in treating aggressive brain tumors and activating anti-tumor immune responses, showing potential for novel immunomodulatory approaches in pediatric brain cancers. (Words: 82)

Moleculin Biotech, Inc., a Phase 3 clinical stage pharmaceutical company, is advancing a pipeline of therapeutic candidates to tackle hard-to-treat tumors and viruses. Their lead program, Annamycin, is showing promise in treating relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. Additionally, the company is developing WP1066, an Immune/Transcription Modulator for brain tumors, pancreatic, and other cancers, as well as a portfolio of antimetabolites for potential virus treatment and cancer indications. The company is actively involved in pivotal Phase 3 trials for their lead programs. (Words: 87)

Read more at GlobeNewswire: Moleculin Announces Positive Results from Phase 1 Clinical